Immunotech Laboratories Announces Successful Completion Of Phase 1 And Phase 2 Field Trials Of The Company’s Patented Treatment Of The HIV/AIDS And Hepatitis C Viruses
8/28/2014 10:41:26 AM
MONROVIA, Calif.--(BUSINESS WIRE)--Immunotech Laboratories, Inc. (OTCMARKETS:IMMB) Immunotech Laboratories, Inc. announced today that the Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG (“IMMB-BG”) a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization (“CRO”) to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility.
Help employers find you! Check out all the jobs and post your resume.
comments powered by